Journal article

Iatrogenic Creutzfeldt-Jakob disease with Amyloid-beta pathology: an international study

Ignazio Cali, Mark L Cohen, Stephane Haik, Piero Parchi, Giorgio Giaccone, Steven J Collins, Diane Kofskey, Han Wang, Catriona A McLean, Jean-Philippe Brandel, Nicolas Privat, Veronique Sazdovitch, Charles Duyckaerts, Tetsuyuki Kitamoto, Ermias D Belay, Ryan A Maddox, Fabrizio Tagliavini, Maurizio Pocchiari, Ellen Leschek, Brian S Appleby Show all

ACTA NEUROPATHOLOGICA COMMUNICATIONS | BIOMED CENTRAL LTD | Published : 2018

Abstract

The presence of pathology related to the deposition of amyloid-β (Aβ) has been recently reported in iatrogenic Creutzfeldt-Jakob disease (iCJD) acquired from inoculation of growth hormone (GH) extracted from human cadaveric pituitary gland or use of cadaveric dura mater (DM) grafts.To investigate this phenomenon further, a cohort of 27 iCJD cases - 21 with adequate number of histopathological sections - originating from Australia, France, Italy, and the Unites States, were examined by immunohistochemistry, amyloid staining, and Western blot analysis of the scrapie prion protein (PrPSc), and compared with age-group matched cases of sporadic CJD (sCJD), Alzheimer disease (AD) or free of neurod..

View full abstract

Grants

Awarded by CDC


Awarded by NIH


Awarded by program "Investissements 276 d'avenir"


Awarded by NHMRC


Awarded by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES


Awarded by NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE


Awarded by NATIONAL INSTITUTE ON AGING


Funding Acknowledgements

This work was supported by: CDC 000309CK14 to J.G. Safar; NIH P01AI106705, NIH 5R01NS083687 and Charles S. Britton Fund. to P. Gambetti; The Reseau National de Reference de maladies de Creutzfeldt-Jakob and the "Centre National de Reference des agents transmissibles non conventionnels" (Paris, France) are supported by Sante Publique France; Inserm 1127 has received funding from the program "Investissements 276 d'avenir" ANR-10-IAIHU-06; Italian Ministry of Health funding to F. Tagliavini; Stivison Fund for CJD Research to B.S. Appleby; The Australian National Creutzfeldt-Jakob Disease Registry is funded by the Commonwealth Department of Health and S. Collins is funded in part by a NHMRC Practitioner Fellowship (# APP1105784); Grant-in-Aid for Scientific Research on Innovative Areas (Brain Protein Aging and Dementia Control) from MEXT to T. Kitamoto.